#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Acrylamide , a thermal processing contaminant with a low molecular weight , which is soluble in water , is formed when carbohydrate-rich foods are subjected to temperatures above 120 °C in low-moisture conditions , such as frying , roasting or baking .
3-1	17-27	Acrylamide	substance	new	coref	4-12
3-2	28-29	,	_	_	_	_
3-3	30-31	a	abstract[5]	new[5]	coref	9-17[95_5]
3-4	32-39	thermal	abstract[5]	new[5]	_	_
3-5	40-50	processing	abstract|abstract[5]	new|new[5]	_	_
3-6	51-62	contaminant	abstract[5]	new[5]	_	_
3-7	63-67	with	abstract[5]	new[5]	_	_
3-8	68-69	a	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-9	70-73	low	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-10	74-83	molecular	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-11	84-90	weight	abstract[5]|abstract[6]	new[5]|new[6]	_	_
3-12	91-92	,	_	_	_	_
3-13	93-98	which	_	_	_	_
3-14	99-101	is	_	_	_	_
3-15	102-109	soluble	_	_	_	_
3-16	110-112	in	_	_	_	_
3-17	113-118	water	substance	new	_	_
3-18	119-120	,	_	_	_	_
3-19	121-123	is	_	_	_	_
3-20	124-130	formed	_	_	_	_
3-21	131-135	when	_	_	_	_
3-22	136-153	carbohydrate-rich	substance[8]	new[8]	coref	4-31[29_8]
3-23	154-159	foods	substance[8]	new[8]	_	_
3-24	160-163	are	_	_	_	_
3-25	164-173	subjected	_	_	_	_
3-26	174-176	to	_	_	_	_
3-27	177-189	temperatures	abstract	new	_	_
3-28	190-195	above	abstract[10]	new[10]	_	_
3-29	196-199	120	abstract[10]	new[10]	_	_
3-30	200-202	°C	abstract[10]	new[10]	_	_
3-31	203-205	in	abstract[10]	new[10]	_	_
3-32	206-218	low-moisture	abstract[10]|abstract[11]	new[10]|new[11]	coref	18-35[195_11]
3-33	219-229	conditions	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-34	230-231	,	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-35	232-236	such	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-36	237-239	as	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-37	240-246	frying	abstract[10]|abstract[11]|event	new[10]|new[11]|new	_	_
3-38	247-248	,	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-39	249-257	roasting	abstract[10]|abstract[11]|abstract	new[10]|new[11]|new	_	_
3-40	258-260	or	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-41	261-267	baking	abstract[10]|abstract[11]|person	new[10]|new[11]|new	_	_
3-42	268-269	.	_	_	_	_

#Text=Several studies consider Maillard reactions to be the main pathway for acrylamide , 5 hydroxymethylfurfural , methylglyoxal – lysine dimers , Nε – carboxymethyl – lysine and pyrraline formation in processed foods , particularly reactions between the carbonyl group of reducing sugars and amino acids .
4-1	270-277	Several	abstract[15]	new[15]	coref	13-17[142_15]
4-2	278-285	studies	abstract[15]	new[15]	_	_
4-3	286-294	consider	_	_	_	_
4-4	295-303	Maillard	person|event[17]	new|new[17]	appos|appos	4-34[30_17]|4-34[30_17]
4-5	304-313	reactions	event[17]	new[17]	_	_
4-6	314-316	to	_	_	_	_
4-7	317-319	be	_	_	_	_
4-8	320-323	the	place[18]	new[18]	_	_
4-9	324-328	main	place[18]	new[18]	_	_
4-10	329-336	pathway	place[18]	new[18]	_	_
4-11	337-340	for	place[18]	new[18]	_	_
4-12	341-351	acrylamide	place[18]|substance	new[18]|giv	coref	5-8
4-13	352-353	,	place[18]	new[18]	_	_
4-14	354-355	5	place[18]|substance[20]	new[18]|new[20]	_	_
4-15	356-377	hydroxymethylfurfural	place[18]|substance[20]	new[18]|new[20]	_	_
4-16	378-379	,	place[18]	new[18]	_	_
4-17	380-393	methylglyoxal	place[18]|substance	new[18]|new	_	_
4-18	394-395	–	place[18]	new[18]	_	_
4-19	396-402	lysine	place[18]|abstract|substance[23]	new[18]|new|new[23]	coref|coref	4-26|4-26
4-20	403-409	dimers	place[18]|substance[23]	new[18]|new[23]	_	_
4-21	410-411	,	place[18]	new[18]	_	_
4-22	412-414	Nε	place[18]|substance[24]	new[18]|new[24]	_	_
4-23	415-416	–	place[18]|substance[24]	new[18]|new[24]	_	_
4-24	417-430	carboxymethyl	place[18]|substance[24]|substance	new[18]|new[24]|new	_	_
4-25	431-432	–	_	_	_	_
4-26	433-439	lysine	substance|abstract[28]	giv|new[28]	coref|coref	10-18[101_28]|10-18[101_28]
4-27	440-443	and	abstract[28]	new[28]	_	_
4-28	444-453	pyrraline	abstract|abstract[28]	new|new[28]	_	_
4-29	454-463	formation	abstract[28]	new[28]	_	_
4-30	464-466	in	abstract[28]	new[28]	_	_
4-31	467-476	processed	abstract[28]|substance[29]	new[28]|giv[29]	_	_
4-32	477-482	foods	abstract[28]|substance[29]	new[28]|giv[29]	_	_
4-33	483-484	,	_	_	_	_
4-34	485-497	particularly	event[30]	giv[30]	_	_
4-35	498-507	reactions	event[30]	giv[30]	_	_
4-36	508-515	between	event[30]	giv[30]	_	_
4-37	516-519	the	event[30]|person[32]	giv[30]|new[32]	_	_
4-38	520-528	carbonyl	event[30]|abstract|person[32]	giv[30]|new|new[32]	_	_
4-39	529-534	group	event[30]|person[32]	giv[30]|new[32]	_	_
4-40	535-537	of	_	_	_	_
4-41	538-546	reducing	_	_	_	_
4-42	547-553	sugars	substance	new	_	_
4-43	554-557	and	_	_	_	_
4-44	558-563	amino	substance[34]	new[34]	_	_
4-45	564-569	acids	substance[34]	new[34]	_	_
4-46	570-571	.	_	_	_	_

#Text=Initial reports showed relatively high concentrations of acrylamide in high-carbohydrate foodstuffs , such as crispy bread , breakfast cereals , pastries , coffee , French fries and crisps .
5-1	572-579	Initial	abstract[35]	new[35]	_	_
5-2	580-587	reports	abstract[35]	new[35]	_	_
5-3	588-594	showed	_	_	_	_
5-4	595-605	relatively	animal[36]	new[36]	_	_
5-5	606-610	high	animal[36]	new[36]	_	_
5-6	611-625	concentrations	animal[36]	new[36]	_	_
5-7	626-628	of	animal[36]	new[36]	_	_
5-8	629-639	acrylamide	animal[36]|substance	new[36]|giv	coref	6-8
5-9	640-642	in	animal[36]	new[36]	_	_
5-10	643-660	high-carbohydrate	animal[36]|substance[38]	new[36]|new[38]	_	_
5-11	661-671	foodstuffs	animal[36]|substance[38]	new[36]|new[38]	_	_
5-12	672-673	,	animal[36]|substance[38]	new[36]|new[38]	_	_
5-13	674-678	such	animal[36]|substance[38]	new[36]|new[38]	_	_
5-14	679-681	as	animal[36]|substance[38]	new[36]|new[38]	_	_
5-15	682-688	crispy	animal[36]|substance[38]|object[39]	new[36]|new[38]|new[39]	_	_
5-16	689-694	bread	animal[36]|substance[38]|object[39]	new[36]|new[38]|new[39]	_	_
5-17	695-696	,	animal[36]|substance[38]	new[36]|new[38]	_	_
5-18	697-706	breakfast	animal[36]|substance[38]|substance[40]	new[36]|new[38]|new[40]	_	_
5-19	707-714	cereals	animal[36]|substance[38]|substance[40]	new[36]|new[38]|new[40]	_	_
5-20	715-716	,	animal[36]|substance[38]	new[36]|new[38]	_	_
5-21	717-725	pastries	animal[36]|substance[38]|object	new[36]|new[38]|new	_	_
5-22	726-727	,	animal[36]|substance[38]	new[36]|new[38]	_	_
5-23	728-734	coffee	animal[36]|substance[38]|substance	new[36]|new[38]|new	_	_
5-24	735-736	,	animal[36]|substance[38]	new[36]|new[38]	_	_
5-25	737-743	French	animal[36]|substance[38]|object[43]	new[36]|new[38]|new[43]	_	_
5-26	744-749	fries	animal[36]|substance[38]|object[43]	new[36]|new[38]|new[43]	_	_
5-27	750-753	and	animal[36]|substance[38]	new[36]|new[38]	_	_
5-28	754-760	crisps	animal[36]|substance[38]|object	new[36]|new[38]|new	coref	8-28
5-29	761-762	.	_	_	_	_

#Text=In general , potato products present higher acrylamide contents ( 250 – 4000 µg kg−1 ) compared to other food products , because of the higher concentration of asparagine in potato tubers .
6-1	763-765	In	_	_	_	_
6-2	766-773	general	abstract	new	_	_
6-3	774-775	,	_	_	_	_
6-4	776-782	potato	object|object[47]	new|new[47]	coref|coref|coref|coref	6-19[54_47]|6-31|6-19[54_47]|6-31
6-5	783-791	products	object[47]	new[47]	_	_
6-6	792-799	present	_	_	_	_
6-7	800-806	higher	quantity[49]	new[49]	appos	6-11[50_49]
6-8	807-817	acrylamide	substance|quantity[49]	giv|new[49]	coref	7-1
6-9	818-826	contents	quantity[49]	new[49]	_	_
6-10	827-828	(	_	_	_	_
6-11	829-832	250	quantity[50]	giv[50]	_	_
6-12	833-834	–	quantity[50]	giv[50]	_	_
6-13	835-839	4000	quantity[50]|quantity	giv[50]|new	_	_
6-14	840-842	µg	quantity[50]|abstract|quantity[53]	giv[50]|new|new[53]	_	_
6-15	843-847	kg−1	quantity[50]|quantity[53]	giv[50]|new[53]	_	_
6-16	848-849	)	_	_	_	_
6-17	850-858	compared	_	_	_	_
6-18	859-861	to	_	_	_	_
6-19	862-867	other	object[54]	giv[54]	_	_
6-20	868-872	food	object[54]	giv[54]	_	_
6-21	873-881	products	object[54]	giv[54]	_	_
6-22	882-883	,	_	_	_	_
6-23	884-891	because	_	_	_	_
6-24	892-894	of	_	_	_	_
6-25	895-898	the	abstract[55]	new[55]	_	_
6-26	899-905	higher	abstract[55]	new[55]	_	_
6-27	906-919	concentration	abstract[55]	new[55]	_	_
6-28	920-922	of	abstract[55]	new[55]	_	_
6-29	923-933	asparagine	abstract[55]|substance[56]	new[55]|new[56]	_	_
6-30	934-936	in	abstract[55]|substance[56]	new[55]|new[56]	_	_
6-31	937-943	potato	abstract[55]|substance[56]|object|plant[58]	new[55]|new[56]|giv|new[58]	coref|coref	10-61|10-61
6-32	944-950	tubers	abstract[55]|substance[56]|plant[58]	new[55]|new[56]|new[58]	_	_
6-33	951-952	.	_	_	_	_

#Text=Acrylamide has been classified by the Agency for Research on Cancer as “ probably carcinogenic to humans ” ( Group 2A ) and , in the latest report from the European Food Safety Authority Expert Panel on Contaminants in the Food Chain ( CONTAM , 2015 ) , the margins of exposure for acrylamide lead to concerns regarding their neoplastic effects , based on animal evidence .
7-1	953-963	Acrylamide	substance	giv	coref	7-54
7-2	964-967	has	_	_	_	_
7-3	968-972	been	_	_	_	_
7-4	973-983	classified	_	_	_	_
7-5	984-986	by	_	_	_	_
7-6	987-990	the	organization[60]	new[60]	_	_
7-7	991-997	Agency	organization[60]	new[60]	_	_
7-8	998-1001	for	organization[60]	new[60]	_	_
7-9	1002-1010	Research	organization[60]|abstract[61]	new[60]|new[61]	_	_
7-10	1011-1013	on	organization[60]|abstract[61]	new[60]|new[61]	_	_
7-11	1014-1020	Cancer	organization[60]|abstract[61]|abstract	new[60]|new[61]|new	_	_
7-12	1021-1023	as	_	_	_	_
7-13	1024-1025	“	_	_	_	_
7-14	1026-1034	probably	_	_	_	_
7-15	1035-1047	carcinogenic	_	_	_	_
7-16	1048-1050	to	_	_	_	_
7-17	1051-1057	humans	person	new	coref	14-4
7-18	1058-1059	”	_	_	_	_
7-19	1060-1061	(	_	_	_	_
7-20	1062-1067	Group	_	_	_	_
7-21	1068-1070	2A	_	_	_	_
7-22	1071-1072	)	_	_	_	_
7-23	1073-1076	and	_	_	_	_
7-24	1077-1078	,	_	_	_	_
7-25	1079-1081	in	_	_	_	_
7-26	1082-1085	the	abstract[64]	new[64]	_	_
7-27	1086-1092	latest	abstract[64]	new[64]	_	_
7-28	1093-1099	report	abstract[64]	new[64]	_	_
7-29	1100-1104	from	abstract[64]	new[64]	_	_
7-30	1105-1108	the	abstract[64]|person[68]	new[64]|new[68]	_	_
7-31	1109-1117	European	abstract[64]|substance[65]|person[68]	new[64]|new[65]|new[68]	coref	7-41[0_65]
7-32	1118-1122	Food	abstract[64]|substance[65]|person[68]	new[64]|new[65]|new[68]	_	_
7-33	1123-1129	Safety	abstract[64]|abstract|person[68]	new[64]|new|new[68]	_	_
7-34	1130-1139	Authority	abstract[64]|organization|person[68]	new[64]|new|new[68]	_	_
7-35	1140-1146	Expert	abstract[64]|person[68]	new[64]|new[68]	_	_
7-36	1147-1152	Panel	abstract[64]|person[68]	new[64]|new[68]	_	_
7-37	1153-1155	on	abstract[64]|person[68]	new[64]|new[68]	_	_
7-38	1156-1168	Contaminants	abstract[64]|person[68]|person	new[64]|new[68]|new	ana	7-59
7-39	1169-1171	in	abstract[64]|person[68]	new[64]|new[68]	_	_
7-40	1172-1175	the	abstract[64]|person[68]|abstract[71]	new[64]|new[68]|new[71]	_	_
7-41	1176-1180	Food	abstract[64]|person[68]|substance|abstract[71]	new[64]|new[68]|giv|new[71]	coref	8-18
7-42	1181-1186	Chain	abstract[64]|person[68]|abstract[71]	new[64]|new[68]|new[71]	_	_
7-43	1187-1188	(	_	_	_	_
7-44	1189-1195	CONTAM	object[72]	new[72]	_	_
7-45	1196-1197	,	object[72]	new[72]	_	_
7-46	1198-1202	2015	object[72]	new[72]	_	_
7-47	1203-1204	)	_	_	_	_
7-48	1205-1206	,	_	_	_	_
7-49	1207-1210	the	abstract[73]	new[73]	_	_
7-50	1211-1218	margins	abstract[73]	new[73]	_	_
7-51	1219-1221	of	abstract[73]	new[73]	_	_
7-52	1222-1230	exposure	abstract[73]|abstract	new[73]|new	_	_
7-53	1231-1234	for	abstract[73]	new[73]	_	_
7-54	1235-1245	acrylamide	abstract[73]|substance|abstract[76]	new[73]|giv|new[76]	coref|coref	8-16[85_0]|8-16[85_0]
7-55	1246-1250	lead	abstract[73]|abstract[76]	new[73]|new[76]	_	_
7-56	1251-1253	to	abstract[73]|abstract[76]	new[73]|new[76]	_	_
7-57	1254-1262	concerns	abstract[73]|abstract[76]|abstract	new[73]|new[76]|new	_	_
7-58	1263-1272	regarding	_	_	_	_
7-59	1273-1278	their	person|abstract[79]	giv|new[79]	coref|coref	17-11|17-11
7-60	1279-1289	neoplastic	abstract[79]	new[79]	_	_
7-61	1290-1297	effects	abstract[79]	new[79]	_	_
7-62	1298-1299	,	_	_	_	_
7-63	1300-1305	based	_	_	_	_
7-64	1306-1308	on	_	_	_	_
7-65	1309-1315	animal	animal|abstract[81]	new|new[81]	_	_
7-66	1316-1324	evidence	abstract[81]	new[81]	_	_
7-67	1325-1326	.	_	_	_	_

#Text=Therefore , the European Commission recently established “ indicative ” levels for the presence of acrylamide in food , suggesting a limit of 750 µg kg−1 for crisps .
8-1	1327-1336	Therefore	_	_	_	_
8-2	1337-1338	,	_	_	_	_
8-3	1339-1342	the	organization[82]	new[82]	_	_
8-4	1343-1351	European	organization[82]	new[82]	_	_
8-5	1352-1362	Commission	organization[82]	new[82]	_	_
8-6	1363-1371	recently	_	_	_	_
8-7	1372-1383	established	_	_	_	_
8-8	1384-1385	“	abstract[83]	new[83]	coref	11-16[120_83]
8-9	1386-1396	indicative	abstract[83]	new[83]	_	_
8-10	1397-1398	”	abstract[83]	new[83]	_	_
8-11	1399-1405	levels	abstract[83]	new[83]	_	_
8-12	1406-1409	for	abstract[83]	new[83]	_	_
8-13	1410-1413	the	abstract[83]|abstract[84]	new[83]|new[84]	_	_
8-14	1414-1422	presence	abstract[83]|abstract[84]	new[83]|new[84]	_	_
8-15	1423-1425	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
8-16	1426-1436	acrylamide	abstract[83]|abstract[84]|substance[85]	new[83]|new[84]|giv[85]	coref	10-18[0_85]
8-17	1437-1439	in	abstract[83]|abstract[84]|substance[85]	new[83]|new[84]|giv[85]	_	_
8-18	1440-1444	food	abstract[83]|abstract[84]|substance[85]|substance	new[83]|new[84]|giv[85]|giv	coref	9-10
8-19	1445-1446	,	_	_	_	_
8-20	1447-1457	suggesting	_	_	_	_
8-21	1458-1459	a	abstract[87]	new[87]	_	_
8-22	1460-1465	limit	abstract[87]	new[87]	_	_
8-23	1466-1468	of	abstract[87]	new[87]	_	_
8-24	1469-1472	750	abstract[87]|quantity[88]	new[87]|new[88]	_	_
8-25	1473-1475	µg	abstract[87]|quantity[88]	new[87]|new[88]	_	_
8-26	1476-1480	kg−1	abstract[87]|quantity[88]	new[87]|new[88]	_	_
8-27	1481-1484	for	abstract[87]|quantity[88]	new[87]|new[88]	_	_
8-28	1485-1491	crisps	abstract[87]|quantity[88]|substance	new[87]|new[88]|giv	coref	13-28
8-29	1492-1493	.	_	_	_	_

#Text=Previously , the European Union and FDA had encouraged food industries to reduce the presence of this contaminant .
9-1	1494-1504	Previously	_	_	_	_
9-2	1505-1506	,	_	_	_	_
9-3	1507-1510	the	organization[90]	new[90]	_	_
9-4	1511-1519	European	organization[90]	new[90]	_	_
9-5	1520-1525	Union	organization[90]	new[90]	_	_
9-6	1526-1529	and	_	_	_	_
9-7	1530-1533	FDA	organization	new	_	_
9-8	1534-1537	had	_	_	_	_
9-9	1538-1548	encouraged	_	_	_	_
9-10	1549-1553	food	substance|abstract[93]	giv|new[93]	coref|coref|coref|coref	10-7|11-7[116_93]|10-7|11-7[116_93]
9-11	1554-1564	industries	abstract[93]	new[93]	_	_
9-12	1565-1567	to	_	_	_	_
9-13	1568-1574	reduce	_	_	_	_
9-14	1575-1578	the	abstract[94]	new[94]	_	_
9-15	1579-1587	presence	abstract[94]	new[94]	_	_
9-16	1588-1590	of	abstract[94]	new[94]	_	_
9-17	1591-1595	this	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
9-18	1596-1607	contaminant	abstract[94]|abstract[95]	new[94]|giv[95]	_	_
9-19	1608-1609	.	_	_	_	_

#Text=In response to this , the food industry has been forced to apply different strategies to reduce acrylamide formation , applying processing modifications according to recommendations published by the European Food and Drink Federation in the document “ Acrylamide Toolbox ” , which includes the following variables : temperature and time during frying , blanching treatment , and thickness of potato slices .
10-1	1610-1612	In	_	_	_	_
10-2	1613-1621	response	abstract[96]	new[96]	_	_
10-3	1622-1624	to	abstract[96]	new[96]	_	_
10-4	1625-1629	this	abstract[96]	new[96]	_	_
10-5	1630-1631	,	_	_	_	_
10-6	1632-1635	the	organization[98]	new[98]	_	_
10-7	1636-1640	food	substance|organization[98]	giv|new[98]	coref	10-30[104_0]
10-8	1641-1649	industry	organization[98]	new[98]	_	_
10-9	1650-1653	has	_	_	_	_
10-10	1654-1658	been	_	_	_	_
10-11	1659-1665	forced	_	_	_	_
10-12	1666-1668	to	_	_	_	_
10-13	1669-1674	apply	_	_	_	_
10-14	1675-1684	different	abstract[99]	new[99]	coref	19-5[199_99]
10-15	1685-1695	strategies	abstract[99]	new[99]	_	_
10-16	1696-1698	to	_	_	_	_
10-17	1699-1705	reduce	_	_	_	_
10-18	1706-1716	acrylamide	substance|abstract[101]	giv|giv[101]	coref|coref	10-39|10-39
10-19	1717-1726	formation	abstract[101]	giv[101]	_	_
10-20	1727-1728	,	_	_	_	_
10-21	1729-1737	applying	_	_	_	_
10-22	1738-1748	processing	_	_	_	_
10-23	1749-1762	modifications	abstract[102]	new[102]	_	_
10-24	1763-1772	according	abstract[102]	new[102]	_	_
10-25	1773-1775	to	abstract[102]	new[102]	_	_
10-26	1776-1791	recommendations	abstract[102]|abstract	new[102]|new	_	_
10-27	1792-1801	published	_	_	_	_
10-28	1802-1804	by	_	_	_	_
10-29	1805-1808	the	organization[106]	new[106]	_	_
10-30	1809-1817	European	object[104]|organization[106]	giv[104]|new[106]	coref	11-8[0_104]
10-31	1818-1822	Food	object[104]|organization[106]	giv[104]|new[106]	_	_
10-32	1823-1826	and	organization[106]	new[106]	_	_
10-33	1827-1832	Drink	person|organization[106]	new|new[106]	_	_
10-34	1833-1843	Federation	organization[106]	new[106]	_	_
10-35	1844-1846	in	organization[106]	new[106]	_	_
10-36	1847-1850	the	organization[106]|object[107]	new[106]|new[107]	appos	10-39[109_107]
10-37	1851-1859	document	organization[106]|object[107]	new[106]|new[107]	_	_
10-38	1860-1861	“	_	_	_	_
10-39	1862-1872	Acrylamide	substance|object[109]	giv|giv[109]	coref|ana|coref|ana	11-17|12-2[0_109]|11-17|12-2[0_109]
10-40	1873-1880	Toolbox	object[109]	giv[109]	_	_
10-41	1881-1882	”	_	_	_	_
10-42	1883-1884	,	_	_	_	_
10-43	1885-1890	which	_	_	_	_
10-44	1891-1899	includes	_	_	_	_
10-45	1900-1903	the	abstract[110]	new[110]	appos	10-49[111_110]
10-46	1904-1913	following	abstract[110]	new[110]	_	_
10-47	1914-1923	variables	abstract[110]	new[110]	_	_
10-48	1924-1925	:	_	_	_	_
10-49	1926-1937	temperature	abstract[111]	giv[111]	coref	12-13[0_111]
10-50	1938-1941	and	abstract[111]	giv[111]	_	_
10-51	1942-1946	time	abstract[111]	giv[111]	_	_
10-52	1947-1953	during	abstract[111]	giv[111]	_	_
10-53	1954-1960	frying	abstract[111]	giv[111]	_	_
10-54	1961-1962	,	abstract[111]	giv[111]	_	_
10-55	1963-1972	blanching	abstract[111]	giv[111]	_	_
10-56	1973-1982	treatment	abstract[111]	giv[111]	_	_
10-57	1983-1984	,	abstract[111]	giv[111]	_	_
10-58	1985-1988	and	abstract[111]	giv[111]	_	_
10-59	1989-1998	thickness	abstract[111]	giv[111]	_	_
10-60	1999-2001	of	abstract[111]	giv[111]	_	_
10-61	2002-2008	potato	abstract[111]|object|object[113]	giv[111]|giv|new[113]	coref|coref	11-13|11-13
10-62	2009-2015	slices	abstract[111]|object[113]	giv[111]|new[113]	_	_
10-63	2016-2017	.	_	_	_	_

#Text=However , the main challenge for the food industries is in producing potato chips with low acrylamide levels without affecting their sensory properties .
11-1	2018-2025	However	_	_	_	_
11-2	2026-2027	,	_	_	_	_
11-3	2028-2031	the	abstract[114]	new[114]	_	_
11-4	2032-2036	main	abstract[114]	new[114]	_	_
11-5	2037-2046	challenge	abstract[114]	new[114]	_	_
11-6	2047-2050	for	abstract[114]	new[114]	_	_
11-7	2051-2054	the	abstract[114]|abstract[116]	new[114]|giv[116]	_	_
11-8	2055-2059	food	abstract[114]|object|abstract[116]	new[114]|giv|giv[116]	coref	13-10
11-9	2060-2070	industries	abstract[114]|abstract[116]	new[114]|giv[116]	_	_
11-10	2071-2073	is	_	_	_	_
11-11	2074-2076	in	_	_	_	_
11-12	2077-2086	producing	_	_	_	_
11-13	2087-2093	potato	object|object[118]	giv|new[118]	ana|coref|ana|coref	11-21[0_118]|13-1|11-21[0_118]|13-1
11-14	2094-2099	chips	object[118]	new[118]	_	_
11-15	2100-2104	with	_	_	_	_
11-16	2105-2108	low	abstract[120]	giv[120]	ana	12-25[0_120]
11-17	2109-2119	acrylamide	substance|abstract[120]	giv|giv[120]	coref	12-16
11-18	2120-2126	levels	abstract[120]	giv[120]	_	_
11-19	2127-2134	without	_	_	_	_
11-20	2135-2144	affecting	_	_	_	_
11-21	2145-2150	their	object|abstract[122]	giv|new[122]	coref|coref|coref|coref	13-1[138_0]|19-21[205_122]|13-1[138_0]|19-21[205_122]
11-22	2151-2158	sensory	abstract[122]	new[122]	_	_
11-23	2159-2169	properties	abstract[122]	new[122]	_	_
11-24	2170-2171	.	_	_	_	_

#Text=Although it is important to evaluate the effect of pre-treatments on the frying process on acrylamide mitigation , it is also necessary to determine their influence on its bioavailability .
12-1	2172-2180	Although	_	_	_	_
12-2	2181-2183	it	object	giv	_	_
12-3	2184-2186	is	_	_	_	_
12-4	2187-2196	important	_	_	_	_
12-5	2197-2199	to	person[124]	new[124]	_	_
12-6	2200-2208	evaluate	person[124]	new[124]	_	_
12-7	2209-2212	the	person[124]|abstract[125]	new[124]|new[125]	_	_
12-8	2213-2219	effect	person[124]|abstract[125]	new[124]|new[125]	_	_
12-9	2220-2222	of	person[124]|abstract[125]	new[124]|new[125]	_	_
12-10	2223-2237	pre-treatments	person[124]|abstract[125]|substance	new[124]|new[125]|new	_	_
12-11	2238-2240	on	person[124]|abstract[125]	new[124]|new[125]	_	_
12-12	2241-2244	the	person[124]|abstract[125]|event[128]	new[124]|new[125]|new[128]	coref	13-32[147_128]
12-13	2245-2251	frying	person[124]|abstract[125]|abstract|event[128]	new[124]|new[125]|giv|new[128]	_	_
12-14	2252-2259	process	person[124]|abstract[125]|event[128]	new[124]|new[125]|new[128]	_	_
12-15	2260-2262	on	person[124]|abstract[125]|event[128]	new[124]|new[125]|new[128]	_	_
12-16	2263-2273	acrylamide	person[124]|abstract[125]|event[128]|substance|substance[130]	new[124]|new[125]|new[128]|giv|new[130]	coref|coref|coref|coref	13-26|19-7[0_130]|13-26|19-7[0_130]
12-17	2274-2284	mitigation	person[124]|abstract[125]|event[128]|substance[130]	new[124]|new[125]|new[128]|new[130]	_	_
12-18	2285-2286	,	_	_	_	_
12-19	2287-2289	it	abstract	new	cata	12-19[0_132]
12-20	2290-2292	is	_	_	_	_
12-21	2293-2297	also	_	_	_	_
12-22	2298-2307	necessary	_	_	_	_
12-23	2308-2310	to	abstract[132]	new[132]	ana	12-28[0_132]
12-24	2311-2320	determine	abstract[132]	new[132]	_	_
12-25	2321-2326	their	abstract[132]|abstract|abstract[134]	new[132]|giv|new[134]	coref|coref	19-18[204_134]|19-18[204_134]
12-26	2327-2336	influence	abstract[132]|abstract[134]	new[132]|new[134]	_	_
12-27	2337-2339	on	_	_	_	_
12-28	2340-2343	its	abstract|abstract[136]	giv|new[136]	coref|coref	13-23[143_136]|13-23[143_136]
12-29	2344-2359	bioavailability	abstract[136]	new[136]	_	_
12-30	2360-2361	.	_	_	_	_

#Text=Potato chips are an important part of the snack food market in many countries , and few studies have been published about the bioavailability of acrylamide after crisps have been through the digestion process .
13-1	2362-2368	Potato	object|substance[138]	giv|giv[138]	_	_
13-2	2369-2374	chips	substance[138]	giv[138]	_	_
13-3	2375-2378	are	_	_	_	_
13-4	2379-2381	an	_	_	_	_
13-5	2382-2391	important	_	_	_	_
13-6	2392-2396	part	_	_	_	_
13-7	2397-2399	of	_	_	_	_
13-8	2400-2403	the	abstract[140]	new[140]	_	_
13-9	2404-2409	snack	abstract[140]	new[140]	_	_
13-10	2410-2414	food	object|abstract[140]	giv|new[140]	coref	14-8
13-11	2415-2421	market	abstract[140]	new[140]	_	_
13-12	2422-2424	in	_	_	_	_
13-13	2425-2429	many	place[141]	new[141]	_	_
13-14	2430-2439	countries	place[141]	new[141]	_	_
13-15	2440-2441	,	_	_	_	_
13-16	2442-2445	and	_	_	_	_
13-17	2446-2449	few	abstract[142]	giv[142]	_	_
13-18	2450-2457	studies	abstract[142]	giv[142]	_	_
13-19	2458-2462	have	_	_	_	_
13-20	2463-2467	been	_	_	_	_
13-21	2468-2477	published	_	_	_	_
13-22	2478-2483	about	_	_	_	_
13-23	2484-2487	the	abstract[143]	giv[143]	_	_
13-24	2488-2503	bioavailability	abstract[143]	giv[143]	_	_
13-25	2504-2506	of	abstract[143]	giv[143]	_	_
13-26	2507-2517	acrylamide	abstract[143]|substance	giv[143]|giv	coref	14-1
13-27	2518-2523	after	_	_	_	_
13-28	2524-2530	crisps	object	giv	_	_
13-29	2531-2535	have	_	_	_	_
13-30	2536-2540	been	_	_	_	_
13-31	2541-2548	through	_	_	_	_
13-32	2549-2552	the	event[147]	giv[147]	coref	15-30[167_147]
13-33	2553-2562	digestion	abstract|event[147]	new|giv[147]	coref	15-31
13-34	2563-2570	process	event[147]	giv[147]	_	_
13-35	2571-2572	.	_	_	_	_

#Text=Acrylamide intake in humans occurs mainly via food ingestion , where the total amount of this compound does not necessarily reflect the available amount to the body .
14-1	2573-2583	Acrylamide	substance|event[149]	giv|new[149]	coref|coref	19-6|19-6
14-2	2584-2590	intake	event[149]	new[149]	_	_
14-3	2591-2593	in	event[149]	new[149]	_	_
14-4	2594-2600	humans	event[149]|person	new[149]|giv	_	_
14-5	2601-2607	occurs	_	_	_	_
14-6	2608-2614	mainly	_	_	_	_
14-7	2615-2618	via	_	_	_	_
14-8	2619-2623	food	substance|abstract[152]	giv|new[152]	coref|coref	15-6[158_0]|15-6[158_0]
14-9	2624-2633	ingestion	abstract[152]	new[152]	_	_
14-10	2634-2635	,	_	_	_	_
14-11	2636-2641	where	_	_	_	_
14-12	2642-2645	the	quantity[153]	new[153]	_	_
14-13	2646-2651	total	quantity[153]	new[153]	_	_
14-14	2652-2658	amount	quantity[153]	new[153]	_	_
14-15	2659-2661	of	quantity[153]	new[153]	_	_
14-16	2662-2666	this	quantity[153]|substance[154]	new[153]|new[154]	coref	16-13[171_154]
14-17	2667-2675	compound	quantity[153]|substance[154]	new[153]|new[154]	_	_
14-18	2676-2680	does	_	_	_	_
14-19	2681-2684	not	_	_	_	_
14-20	2685-2696	necessarily	_	_	_	_
14-21	2697-2704	reflect	_	_	_	_
14-22	2705-2708	the	quantity[155]	new[155]	ana	15-9[0_155]
14-23	2709-2718	available	quantity[155]	new[155]	_	_
14-24	2719-2725	amount	quantity[155]	new[155]	_	_
14-25	2726-2728	to	quantity[155]	new[155]	_	_
14-26	2729-2732	the	quantity[155]|object[156]	new[155]|new[156]	_	_
14-27	2733-2737	body	quantity[155]|object[156]	new[155]|new[156]	_	_
14-28	2738-2739	.	_	_	_	_

#Text=There are chemical changes in the food when it enters the digestive tract , because of pH variations , and the action of several enzymes in every stage of the digestion process .
15-1	2740-2745	There	_	_	_	_
15-2	2746-2749	are	_	_	_	_
15-3	2750-2758	chemical	abstract[157]	new[157]	_	_
15-4	2759-2766	changes	abstract[157]	new[157]	_	_
15-5	2767-2769	in	abstract[157]	new[157]	_	_
15-6	2770-2773	the	abstract[157]|substance[158]	new[157]|giv[158]	coref	16-25[0_158]
15-7	2774-2778	food	abstract[157]|substance[158]	new[157]|giv[158]	_	_
15-8	2779-2783	when	_	_	_	_
15-9	2784-2786	it	quantity	giv	coref	16-10[170_0]
15-10	2787-2793	enters	_	_	_	_
15-11	2794-2797	the	object[160]	new[160]	coref	16-28[176_160]
15-12	2798-2807	digestive	object[160]	new[160]	_	_
15-13	2808-2813	tract	object[160]	new[160]	_	_
15-14	2814-2815	,	object[160]	new[160]	_	_
15-15	2816-2823	because	object[160]	new[160]	_	_
15-16	2824-2826	of	object[160]	new[160]	_	_
15-17	2827-2829	pH	object[160]|abstract|abstract[162]	new[160]|new|new[162]	_	_
15-18	2830-2840	variations	object[160]|abstract[162]	new[160]|new[162]	_	_
15-19	2841-2842	,	_	_	_	_
15-20	2843-2846	and	_	_	_	_
15-21	2847-2850	the	event[163]	new[163]	_	_
15-22	2851-2857	action	event[163]	new[163]	_	_
15-23	2858-2860	of	event[163]	new[163]	_	_
15-24	2861-2868	several	event[163]|abstract[164]	new[163]|new[164]	_	_
15-25	2869-2876	enzymes	event[163]|abstract[164]	new[163]|new[164]	_	_
15-26	2877-2879	in	event[163]|abstract[164]	new[163]|new[164]	_	_
15-27	2880-2885	every	event[163]|abstract[164]|abstract[165]	new[163]|new[164]|new[165]	_	_
15-28	2886-2891	stage	event[163]|abstract[164]|abstract[165]	new[163]|new[164]|new[165]	_	_
15-29	2892-2894	of	event[163]|abstract[164]|abstract[165]	new[163]|new[164]|new[165]	_	_
15-30	2895-2898	the	event[163]|abstract[164]|abstract[165]|event[167]	new[163]|new[164]|new[165]|giv[167]	_	_
15-31	2899-2908	digestion	event[163]|abstract[164]|abstract[165]|abstract|event[167]	new[163]|new[164]|new[165]|giv|giv[167]	coref	19-31
15-32	2909-2916	process	event[163]|abstract[164]|abstract[165]|event[167]	new[163]|new[164]|new[165]|giv[167]	_	_
15-33	2917-2918	.	_	_	_	_

#Text=In this sense , bioaccessibility is used to evaluate the amount of a chemical compound available for absorption after it is released from the food matrix into the gastrointestinal tract .
16-1	2919-2921	In	_	_	_	_
16-2	2922-2926	this	abstract[168]	new[168]	_	_
16-3	2927-2932	sense	abstract[168]	new[168]	_	_
16-4	2933-2934	,	_	_	_	_
16-5	2935-2951	bioaccessibility	substance	new	coref	17-8[178_0]
16-6	2952-2954	is	_	_	_	_
16-7	2955-2959	used	_	_	_	_
16-8	2960-2962	to	_	_	_	_
16-9	2963-2971	evaluate	_	_	_	_
16-10	2972-2975	the	quantity[170]	giv[170]	_	_
16-11	2976-2982	amount	quantity[170]	giv[170]	_	_
16-12	2983-2985	of	quantity[170]	giv[170]	_	_
16-13	2986-2987	a	quantity[170]|substance[171]	giv[170]|giv[171]	ana	16-20[0_171]
16-14	2988-2996	chemical	quantity[170]|substance[171]	giv[170]|giv[171]	_	_
16-15	2997-3005	compound	quantity[170]|substance[171]	giv[170]|giv[171]	_	_
16-16	3006-3015	available	quantity[170]|substance[171]	giv[170]|giv[171]	_	_
16-17	3016-3019	for	_	_	_	_
16-18	3020-3030	absorption	abstract	new	_	_
16-19	3031-3036	after	_	_	_	_
16-20	3037-3039	it	substance	giv	_	_
16-21	3040-3042	is	_	_	_	_
16-22	3043-3051	released	_	_	_	_
16-23	3052-3056	from	_	_	_	_
16-24	3057-3060	the	substance[175]	new[175]	_	_
16-25	3061-3065	food	substance|substance[175]	giv|new[175]	_	_
16-26	3066-3072	matrix	substance[175]	new[175]	_	_
16-27	3073-3077	into	_	_	_	_
16-28	3078-3081	the	object[176]	giv[176]	_	_
16-29	3082-3098	gastrointestinal	object[176]	giv[176]	_	_
16-30	3099-3104	tract	object[176]	giv[176]	_	_
16-31	3105-3106	.	_	_	_	_

#Text=Several methodologies can be used to assess the bioaccessibility of contaminants or nutrients : 1 ) in vitro , 2 ) ex vivo , 3 ) in situ and 4 ) in vivo models .
17-1	3107-3114	Several	abstract[177]	new[177]	_	_
17-2	3115-3128	methodologies	abstract[177]	new[177]	_	_
17-3	3129-3132	can	_	_	_	_
17-4	3133-3135	be	_	_	_	_
17-5	3136-3140	used	_	_	_	_
17-6	3141-3143	to	_	_	_	_
17-7	3144-3150	assess	_	_	_	_
17-8	3151-3154	the	substance[178]	giv[178]	_	_
17-9	3155-3171	bioaccessibility	substance[178]	giv[178]	_	_
17-10	3172-3174	of	substance[178]	giv[178]	_	_
17-11	3175-3187	contaminants	substance[178]|substance	giv[178]|giv	_	_
17-12	3188-3190	or	substance[178]	giv[178]	_	_
17-13	3191-3200	nutrients	substance[178]|substance[180]	giv[178]|new[180]	_	_
17-14	3201-3202	:	substance[178]|substance[180]	giv[178]|new[180]	_	_
17-15	3203-3204	1	substance[178]|substance[180]	giv[178]|new[180]	_	_
17-16	3205-3206	)	_	_	_	_
17-17	3207-3209	in	_	_	_	_
17-18	3210-3215	vitro	_	_	_	_
17-19	3216-3217	,	_	_	_	_
17-20	3218-3219	2	quantity	new	_	_
17-21	3220-3221	)	_	_	_	_
17-22	3222-3224	ex	_	_	_	_
17-23	3225-3229	vivo	_	_	_	_
17-24	3230-3231	,	_	_	_	_
17-25	3232-3233	3	_	_	_	_
17-26	3234-3235	)	_	_	_	_
17-27	3236-3238	in	_	_	_	_
17-28	3239-3243	situ	_	_	_	_
17-29	3244-3247	and	_	_	_	_
17-30	3248-3249	4	time[182]	new[182]	_	_
17-31	3250-3251	)	time[182]	new[182]	_	_
17-32	3252-3254	in	time[182]	new[182]	_	_
17-33	3255-3259	vivo	time[182]|object|abstract[184]	new[182]|new|new[184]	coref|coref|coref|coref	18-8[187_184]|18-16|18-8[187_184]|18-16
17-34	3260-3266	models	time[182]|abstract[184]	new[182]|new[184]	_	_
17-35	3267-3268	.	_	_	_	_

#Text=Among the techniques mentioned before , in vitro models are more commonly used than in vivo models , because of their simplicity , lower cost , lack of ethical issues and good reproducibility under controlled conditions .
18-1	3269-3274	Among	_	_	_	_
18-2	3275-3278	the	abstract[185]	new[185]	_	_
18-3	3279-3289	techniques	abstract[185]	new[185]	_	_
18-4	3290-3299	mentioned	_	_	_	_
18-5	3300-3306	before	_	_	_	_
18-6	3307-3308	,	_	_	_	_
18-7	3309-3311	in	_	_	_	_
18-8	3312-3317	vitro	organization|abstract[187]	new|giv[187]	coref|coref	18-16[189_187]|18-16[189_187]
18-9	3318-3324	models	abstract[187]	giv[187]	_	_
18-10	3325-3328	are	_	_	_	_
18-11	3329-3333	more	_	_	_	_
18-12	3334-3342	commonly	_	_	_	_
18-13	3343-3347	used	_	_	_	_
18-14	3348-3352	than	_	_	_	_
18-15	3353-3355	in	_	_	_	_
18-16	3356-3360	vivo	object|abstract[189]	giv|giv[189]	_	_
18-17	3361-3367	models	abstract[189]	giv[189]	_	_
18-18	3368-3369	,	abstract[189]	giv[189]	_	_
18-19	3370-3377	because	abstract[189]	giv[189]	_	_
18-20	3378-3380	of	abstract[189]	giv[189]	_	_
18-21	3381-3386	their	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
18-22	3387-3397	simplicity	abstract[189]|abstract[190]	giv[189]|new[190]	_	_
18-23	3398-3399	,	abstract[189]	giv[189]	_	_
18-24	3400-3405	lower	abstract[189]|quantity[191]	giv[189]|new[191]	_	_
18-25	3406-3410	cost	abstract[189]|quantity[191]	giv[189]|new[191]	_	_
18-26	3411-3412	,	abstract[189]	giv[189]	_	_
18-27	3413-3417	lack	abstract[189]|abstract[192]	giv[189]|new[192]	_	_
18-28	3418-3420	of	abstract[189]|abstract[192]	giv[189]|new[192]	_	_
18-29	3421-3428	ethical	abstract[189]|abstract[192]|abstract[193]	giv[189]|new[192]|new[193]	_	_
18-30	3429-3435	issues	abstract[189]|abstract[192]|abstract[193]	giv[189]|new[192]|new[193]	_	_
18-31	3436-3439	and	abstract[189]|abstract[192]	giv[189]|new[192]	_	_
18-32	3440-3444	good	abstract[189]|abstract[192]|abstract[194]	giv[189]|new[192]|new[194]	_	_
18-33	3445-3460	reproducibility	abstract[189]|abstract[192]|abstract[194]	giv[189]|new[192]|new[194]	_	_
18-34	3461-3466	under	abstract[189]|abstract[192]|abstract[194]	giv[189]|new[192]|new[194]	_	_
18-35	3467-3477	controlled	abstract[189]|abstract[192]|abstract[194]|abstract[195]	giv[189]|new[192]|new[194]|giv[195]	ana	19-18[0_195]
18-36	3478-3488	conditions	abstract[189]|abstract[192]|abstract[194]|abstract[195]	giv[189]|new[192]|new[194]|giv[195]	_	_
18-37	3489-3490	.	_	_	_	_

#Text=The present work evaluated some acrylamide mitigation strategies , employing a fractional factorial design experiment , and their influence on textural properties and bioaccesibility , by an in vitro simulated digestion assay .
19-1	3491-3494	The	abstract[196]	new[196]	_	_
19-2	3495-3502	present	abstract[196]	new[196]	_	_
19-3	3503-3507	work	abstract[196]	new[196]	_	_
19-4	3508-3517	evaluated	_	_	_	_
19-5	3518-3522	some	abstract[199]	giv[199]	_	_
19-6	3523-3533	acrylamide	substance|abstract[199]	giv|giv[199]	_	_
19-7	3534-3544	mitigation	substance|abstract[199]	giv|giv[199]	_	_
19-8	3545-3555	strategies	abstract[199]	giv[199]	_	_
19-9	3556-3557	,	abstract[199]	giv[199]	_	_
19-10	3558-3567	employing	abstract[199]	giv[199]	_	_
19-11	3568-3569	a	abstract[199]|abstract[202]	giv[199]|new[202]	_	_
19-12	3570-3580	fractional	abstract[199]|abstract[202]	giv[199]|new[202]	_	_
19-13	3581-3590	factorial	abstract[199]|place|abstract[202]	giv[199]|new|new[202]	_	_
19-14	3591-3597	design	abstract[199]|abstract|abstract[202]	giv[199]|new|new[202]	_	_
19-15	3598-3608	experiment	abstract[199]|abstract[202]	giv[199]|new[202]	_	_
19-16	3609-3610	,	abstract[199]	giv[199]	_	_
19-17	3611-3614	and	abstract[199]	giv[199]	_	_
19-18	3615-3620	their	abstract[199]|abstract|abstract[204]	giv[199]|giv|giv[204]	_	_
19-19	3621-3630	influence	abstract[199]|abstract[204]	giv[199]|giv[204]	_	_
19-20	3631-3633	on	abstract[199]|abstract[204]	giv[199]|giv[204]	_	_
19-21	3634-3642	textural	abstract[199]|abstract[204]|abstract[205]	giv[199]|giv[204]|giv[205]	_	_
19-22	3643-3653	properties	abstract[199]|abstract[204]|abstract[205]	giv[199]|giv[204]|giv[205]	_	_
19-23	3654-3657	and	abstract[199]|abstract[204]|abstract[205]	giv[199]|giv[204]|giv[205]	_	_
19-24	3658-3673	bioaccesibility	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-25	3674-3675	,	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-26	3676-3678	by	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-27	3679-3681	an	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-28	3682-3684	in	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-29	3685-3690	vitro	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-30	3691-3700	simulated	abstract[199]|abstract[204]|abstract[205]|substance[206]	giv[199]|giv[204]|giv[205]|new[206]	_	_
19-31	3701-3710	digestion	abstract[199]|abstract[204]|abstract[205]|substance[206]|abstract|abstract[208]	giv[199]|giv[204]|giv[205]|new[206]|giv|new[208]	_	_
19-32	3711-3716	assay	abstract[199]|abstract[204]|abstract[205]|substance[206]|abstract[208]	giv[199]|giv[204]|giv[205]|new[206]|new[208]	_	_
19-33	3717-3718	.	_	_	_	_
